Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL
Autore:
Cheung, MC; Zhao, XQ; Chait, A; Albers, JJ; Brown, BG;
Indirizzi:
Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98103 USA Univ Washington Seattle WA USA 98103 crinol & Nutr, Seattle, WA 98103 USA Univ Washington, Sch Med, Dept Med, Div Cardiol, Seattle, WA 98103 USA Univ Washington Seattle WA USA 98103 , Div Cardiol, Seattle, WA 98103 USA
Titolo Testata:
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
fascicolo: 8, volume: 21, anno: 2001,
pagine: 1320 - 1326
SICI:
1079-5642(200108)21:8<1320:ASBTRO>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
APOLIPOPROTEIN-A-I; DENSITY-LIPOPROTEIN CHOLESTEROL; APOB-CONTAINING LIPOPROTEINS; NICOTINIC-ACID THERAPY; PRIMARY HYPERCHOLESTEROLEMIA; PLASMA-LIPIDS; HEART-DISEASE; SUBFRACTION DISTRIBUTION; METABOLISM; PARTICLES;
Keywords:
coronary artery disease; low HDL; antioxidant vitamins; lipoproteins; HDL particles;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
54
Recensione:
Indirizzi per estratti:
Indirizzo: Cheung, MC Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, 2121 N 35th St, Seattle, WA 98103 USA Univ Washington 2121 N 35th St Seattle WA USA 98103 A 98103 USA
Citazione:
M.C. Cheung et al., "Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL", ART THROM V, 21(8), 2001, pp. 1320-1326

Abstract

One strategy for treating coronary artery disease (CAD) patients with low HDL cholesterol (HDL-C) is to maximally increase. the HDL-C to LDL-C ratio by combining lifestyle changes with niacin (N) plus a statin. Because HDL can prevent LDL oxidation, the low-HDL state also may benefit clinically from supplemental antioxidants. Lipoprotein changes over 12 months were studied in 153 CAD subjects with low HDL-C randomized to take simvastatin and niacin (S-N), antioxidants (vitamins E and C, beta -carotene, and selenium), S-N plus antioxidants (S-N+A), or placebo. Mean baseline plasma cholesterol,triglyceride, LDL-C, and HDL-C levels of the 153 subjects were 196, 207, 127 and 32 mg/dL, respectively. Without S-N, lipid changes were minor. The S-N and S-N+A groups had comparably significant reductions (P less than or equal to0.001) in plasma cholesterol, triglyceride, and LDL-C. However, increases in HDL-C, especially HDL2-C, were consistently higher in the S-N group than in the S-N+A group (25% vs 18% and 42% vs 0%, respectively). With S-N, but not with S-N+A, there was a selective increase in apolipoprotein (apo) A-I (64%) in HDL particles containing apo A-I but not A-H [Lp(A-I)] and their particle size. Thus, in CAD patients with low HDL-C, S-N substantially increased HDL2-C, Lp(A-I), and HDL particle size. These favorable responses were blunted by the antioxidants used owing to a striking selective effect on Lp(A-I). This unexpected adverse interaction between antioxidants andlipid therapy may have important implications for the management of CAD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 14:57:07